Screener
Danaher DHR Diagnostics — Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Danaher in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Danaher’s 10-Q, filed July 21, 2026.
- Filed
- Jul 20, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000313616-26-000161
| For the Three-Month Period Ended June 26, 2026: | Biotechnology / For the Three-Month Period Ended June 26, 2026: | Life Sciences | Diagnostics | Total |
|---|---|---|---|---|
| Western Europe | 689 | 421 | 430 | 1,540 |
| Other developed markets(b) | 74 | 126 | 93 | 293 |
| High-growth markets(c) | 574 | 573 | 811 | 1,958 |
| Total | $1,920 | $1,879 | $2,466 | $6,265 |
| Revenue type: | ||||
| Recurring | $1,722 | $1,268 | $2,210 | $5,200 |
| Nonrecurring | 198 | 611 | 256 | 1,065 |
| Total | $1,920 | $1,879 | $2,466 | $6,265 |
Item 1. Financial Statements
FAQ
- What is Danaher's diagnostics — sales?
- Danaher (DHR) reported diagnostics — sales of $2.47B in Q2 2026.
- How has Danaher's diagnostics — sales changed year-over-year?
- Danaher's diagnostics — sales increased by 6.8% year-over-year, from $2.31B to $2.47B.
- What is the long-term trend for Danaher's diagnostics — sales?
- Over 2 years (2023 to 2025), Danaher's diagnostics — sales has grown at a 1.9% compound annual growth rate (CAGR), from $9.58B to $9.94B.
- What does diagnostics — sales mean?
- Represents the total revenue generated from the sale of diagnostic products, instruments, and related consumables within the segment. This figure reflects the market demand for the company's clinical testing and diagnostic solutions. It serves as a primary indicator of the segment's top-line growth and market penetration.
Ask your AI about Danaher's diagnostics — sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude